Drug pricing and development cost
Everything filed under system in our medical research coverage, the 43 reports filed on it so far.
Caribou Biosciences discontinues CAR-T therapies, cuts staff
Caribou Biosciences is halting development of two off-the-shelf CAR-T cancer therapies, including its Phase 3-ready candidate vispa-cel, and laying...
ArriVent's furmonertinib fails key lung cancer trial endpoint
ArriVent BioPharma's oral lung cancer drug furmonertinib failed to significantly delay tumor progression versus chemotherapy in a late-stage study...
Amgen's Sjögren's drug succeeds in first Phase 3 trial
Amgen's experimental drug dazodalibep met its primary goal in a Phase 3 study for Sjögren's syndrome, showing early and sustained symptom improvement.
Novo Nordisk partners with Anthropic to accelerate drug discovery
Novo Nordisk has entered a collaboration with AI company Anthropic to speed up drug discovery and development.
FDA launches pilot to accelerate phase 1 trials
The FDA has opened a pilot program pairing drug sponsors with qualified research institutions to expedite IND reviews.
Cullinan and Taiho drug extends lung cancer progression-free survival
In a phase 3 trial, adding zipalertinib to chemotherapy improved median progression-free survival to 14.5 months, a six-month gain over chemo alone.
GSK's risvutatug rezetecan shows 18.5-month median overall survival
GSK and Hansoh Pharma's antibody-drug conjugate risvutatug rezetecan achieved a median overall survival of 18.5 months in a phase 3 trial for...
IL-33 Inhibitor Tozorakimab Cuts COPD Exacerbations
The biologic drug tozorakimab, which targets interleukin-33, significantly reduced the rate of moderate and severe exacerbations in patients with...
GLP-1 Drugs Linked to Fewer Asthma, COPD Attacks in Study
A large real-world study presented at the ERS Congress found patients with asthma or COPD who started a GLP-1 drug had a 14% lower risk of severe...
Roivant's lung hypertension drug hits Phase 2 goals
Roivant's mosliciguat reduced a key lung pressure measure by 56% in a Phase 2 trial for PH-ILD, with analysts citing multi-billion dollar potential.
Novartis Phase 3 Trial Fails for Lp(a) Drug Pelacarsen
Novartis's pelacarsen, an antisense drug developed with Ionis to lower lipoprotein(a), did not reduce major cardiovascular events in high-risk...
Novo Nordisk ends two more phase 3 trials
Novo Nordisk has discontinued two late-stage heart failure trials for its drug ziltivekimab after a data review.
Induced Proximity Therapies Gain Ground After First PROTAC Approval
The first FDA-approved PROTAC drug for breast cancer has validated a new class of medicines that work by bringing proteins together.
Novartis, Ionis heart drug fails in major Phase 3 trial
Novartis and Ionis Pharmaceuticals' experimental drug pelacarsen failed to reduce heart attacks, strokes or death in a Phase 3 study of over 8,000...
AbbVie's dual-acting myeloma drug etentamig meets Phase 3 endpoint
AbbVie reported that its bispecific antibody etentamig met the primary endpoint in a Phase 3 trial for multiple myeloma.
FDA Seeks Public Input on Botanical Drug Development
The FDA has launched a public request for information to identify challenges and opportunities in developing botanical prescription drugs.
AI startup Superluminal raises $60M for first drug candidate
AI drug discovery firm Superluminal Medicines has raised $60 million to advance its first candidate, an oral therapy targeting the MC4R receptor.
U.S. Overdose Deaths Drop 27% in 2024
A new Commonwealth Fund report details a sharp decline in U.S. drug overdose deaths in 2024, with preliminary 2025 data showing a continued drop.
Nine Biotechs Join White House Medicaid Pricing Model
Nine mid-sized biopharma firms have agreed to participate in a White House-led Medicaid pricing model, linking U.S.
Natera partners with Angiex on cancer trial
Natera has partnered with Angiex to evaluate its Signatera blood test in a phase 1 trial of the cancer drug AGX101.
Heart Failure Drug Combo Effects Modeled
A pooled analysis of 38,753 patients from nine trials provides individualized estimates for how combinations of modern heart failure drugs affect...
FDA approval ignites orexin drug race
Takeda's orexin-mimicking drug Orzeyful won FDA approval in August for narcolepsy type 1, with experts dubbing the class the 'GLPs of neuroscience'...
Genentech pays $45M for DualityBio ADC pact
Roche's Genentech will pay DualityBio $45 million upfront for rights to antibody-drug conjugates designed for patients who progress after existing...
Syneos Health: Include China Early in Global Clinical Development
Syneos Health advises biotechs to integrate China into global clinical development from the outset.